CNS Pharmaceuticals Inc (CNSP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CNS Pharmaceuticals Inc (CNSP) has a cash flow conversion efficiency ratio of -65.747x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.65 Million) by net assets ($70.70K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CNS Pharmaceuticals Inc balance sheet independence to measure how much of total assets are equity-financed.
CNS Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how CNS Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore debt repayment capacity of CNS Pharmaceuticals Inc to assess how comfortably operating cash covers total debt obligations.
CNS Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CNS Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PRS Reit PLC
LSE:PRSR
|
0.016x |
|
Mex Polska S.A.
WAR:MEX
|
0.244x |
|
Metals Creek Resources Corp
V:MEK
|
-0.234x |
|
Henderson European Focus Trust Plc
LSE:HET
|
0.006x |
|
Adelong Gold Ltd
AU:ADG
|
-0.066x |
|
China Ouhua Winery Holdings
KLSE:5188
|
-0.007x |
|
Unith Ltd
AU:UNT
|
-0.079x |
|
DXN Ltd
AU:DXN
|
-0.368x |
Annual Cash Flow Conversion Efficiency for CNS Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of CNS Pharmaceuticals Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see how much is CNS Pharmaceuticals Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.52 Million | $-13.81 Million | -3.054x | -10.22% |
| 2024-12-31 | $6.18 Million | $-17.11 Million | -2.771x | -186.84% |
| 2023-12-31 | $-4.43 Million | $-14.14 Million | 3.190x | +345.76% |
| 2022-12-31 | $8.13 Million | $-10.56 Million | -1.298x | +36.50% |
| 2021-12-31 | $6.62 Million | $-13.54 Million | -2.045x | -289.68% |
| 2020-12-31 | $13.95 Million | $-7.32 Million | -0.525x | -12.23% |
| 2019-12-31 | $7.60 Million | $-3.55 Million | -0.467x | -135.85% |
| 2018-12-31 | $-549.30K | $-716.38K | 1.304x | -31.96% |
| 2017-12-31 | $-58.53K | $-112.20K | 1.917x | -- |
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate ca… Read more